Adjuvant Therapy After Neoadjuvant Immunochemotherapy Improves Survival in Resected ESCC
This multicenter real-world analysis helps pharmacists weigh whether adding immunotherapy to adjuvant chemotherapy adds value after neoadjuvant immunochemotherapy in resected esophageal squamous cell carcinoma.
Postoperative adjuvant therapy enhances survival for ESCC after neoadjuvant treatment.
Identifying the best postoperative adjuvant therapy for esophageal squamous cell carcinoma (ESCC) after neoadjuvant immunochemotherapy (nICT) is crucial for improving patient outcomes. Postoperative adjuvant chemotherapy (POCT) and chemoimmunotherapy (POICT) both improved overall survival (OS) and disease-free survival (DFS) compared to observation. In non-pathological complete response (non-pCR) patients, both methods were effective, but only POICT helped pathological complete response (pCR) patients. This study highlights that while adding immunotherapy to chemotherapy (POICT) does not significantly extend survival in all matched patients, it may benefit pCR patients specifically. For ESCC patients post-nICT, adjuvant therapy improves survival; POICT may benefit pCR patients more.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Zhang X, Gao H, Cao J, Gao M, Xu Y, Zhang W, Qian P, Liu X, Fu Z, Shen W
Citation:Zhang X, Gao H, Cao J, et al. A real-world multicenter study on postoperative adjuvant treatment patterns and prognostic implications following neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma. Frontiers in immunology. 2026;17:1811836. doi:10.3389/fimmu.2026.1811836